Celcuity Stock Soars 10.24% Ahead of Breast Cancer Trial Results

On July 28, 2025, Celcuity's stock surged by 10.24% in pre-market trading, marking a significant rise ahead of anticipated developments.

Celcuity Inc. has seen a notable increase in its stock price, driven by the upcoming results of a pivotal breast cancer trial. The company's clinical-stage developments have garnered investor attention, contributing to the recent surge in its stock value.

Celcuity's financial performance has also been a key factor in its stock's upward trajectory. The company reported double-digit revenue growth, an expanded gross margin, and an increase in operating profit. These financial metrics reflect the company's disciplined execution and commitment to its strategic goals, further bolstering investor confidence.